

# Supersaturation measurement and modelling

an application for pharmaceutical drug development




# What is supersaturation and why is it interesting?

“an unstable system which has a greater concentration of a material in solution than would exist at equilibrium”

- IUPAC

$$\frac{\text{Solution concentration}}{\text{equilibrium solubility}} > 1$$




# Advanced process modelling workflow

## Introduction

1

Build **flowsheet** model of experiment




3

Estimate parameters and analyse uncertainty


$$J_{prim} = \ln k_n (\Delta C)^n \exp\left(\frac{-E_{A,n}}{RT}\right)$$

$$k_g \exp\left(\frac{-E_{A,g}}{RT}\right) \left(\frac{C_s - C_l}{C_l}\right)^g$$




4

Conduct in vitro and in vivo simulations




2

Execute experiment & capture data



5

Global System Analysis



# Aims and objectives

- An approach that can characterise precipitation over a range of conditions with a single set of parameters is novel
- Workflow
  - Sirius Analytical: Experiments and data
  - Process Systems Enterprise: gCOAS In vitro models, parameter estimation and GSA capabilities
- Demonstrate applicability to a wide range of compounds

Compound	Intrinsic solubility (mg/ml)	pKa	logP
Dibase (ketoconazole)	0.0266	3.29, 6.24	3.7
Ordinary ampholyte (aprepitant)	0.0227	2.8, 8.5	4.5
Neutral (felodipine)	0.053	n/a	1.7
Base (tadalafil)	0.00389	5.39	3.86
Acid (indomethacin)	0.00201	4.2	4.3



# Biorelevant or fundamental study?

## Which approach to take?

**Biorelevant based study:** Design a method mimicking the solution state of a GI transit (pH, dilution, gastric residence and emptying, bile salts and phospholipids). Add the sample as a dosage form or similar. Measure the dissolution and precipitation rates.

- Possible correlation of in vitro supersaturation profile to in vivo data
- Evaluate propensity or risk of precipitation
- Don't learn much about compound

**Property based study:** Find the media conditions where the compound is supersaturated and precipitation is observed. Explore the supersaturation profile at different starting concentrations.


- Understand the fundamental aspects that govern nucleation, induction and crystal growth
- Include excipients and polymers for formulation development
- Not biopredictive



# Typical data output


## Biorelevant based study

**pH shift:** Sample may be either a stock solution or a solid, but must be fully dissolved at start pH. The pH is then shifted/titrated to a target value at a defined temperature (sample must ionisable).



## Property based study



**Solvent quench:** Prepare sample as a stock solution and add a defined volume to the media at a defined temperature and pH (universal method for all sample types).



# Solvent quench method


## Method Overview

1. Use a fixed volume of FaSSIF v1 (40 mL on inForm) maintained at 37°C and find the concentration where instantaneous precipitation occurs (left graph). This is the maximum level of supersaturation.
2. Run some exploratory supersaturation assays below this concentration to observe a sigmoidal shape to the concentration vs. time profile (right graph)
3. Run supersaturation experiments using at least two different supersaturation levels.
4. Measure the induction time, decay constant and extrapolated solubility and fit to Classic Nucleation Theory (CNT).
5. Compare to other sites on selected compounds.






# Hardware Features of the Sirius inForm






## Supersaturation of tadalafil in FaSSIF v1




# Other compounds in the study


Aprepitant in FaSSIF v2




Indomethacin in pH2



Ketoconazole in FaSSIF v2




Felodipine in FaSSIF v1



# Not all compounds follow Classic nucleation theory!

## Fenofibrate in FaSSIF v2



# Workflow recap




# Advanced process modelling workflow

## Introduction

1

Build **flowsheet model** of experiment




3

Estimate parameters and analyse uncertainty


$$J_{prim} = \ln k_n (\Delta C)^n \exp\left(\frac{-E_{A,n}}{RT}\right)$$

$$k_g \exp\left(\frac{-E_{A,g}}{RT}\right) \left(\frac{C_s - C_l}{C_l}\right)^g$$




4

Conduct in vitro and in vivo simulations




2

Execute experiment & capture data



5

Global System Analysis




# Model






# Building a flowsheet model of the experiment



- General system model
  - Solution
    - Contains highly concentrated API
  - In vitro vessel
  - Sensor models
    - Used for measured variables in parameter estimation
- Configured per compound
  - Physiochemical properties
  - Experimental operating procedure

# Model equations (1)

gCOAS in vitro vessel



# Model equations (2)

gCOAS in vitro vessel

- Based on relative supersaturation
  - Freeform - based on intrinsic solubility
  - Salts - solubility product and counterion concentration



- Kinetic model options

- Classical nucleation kinetics

$$J_{prim} = \ln A_0 \left( \frac{-16\pi(\alpha\sigma)^3 v_0^2}{3k^3 T^3 \ln S^2} \right)$$


- Power law nucleation kinetics

$$J_{prim} = \ln k_n (\Delta C)^n \exp\left(\frac{-E_{A,n}}{RT}\right)$$



# Model equations (3)

gCOAS in vitro vessel



## ■ Reaction

$$K_j = \prod_{i=1}^{NC} (C_i)^{v_{ij}}, j = 1, \dots, NR$$

## ■ Diffusion

$$\frac{D_i}{h} (C_i^s - C_i^b), i = 1, \dots, NC$$

## ■ Surface integration limited growth

$$k_g \exp\left(\frac{-E_{A,g}}{RT}\right) \left(\frac{C_s - C_i}{C_i}\right)^g$$

# Parameter estimation




# Importing experimental data

Parameter estimation


Experimental data

Excel spreadsheet titled "Sirius data - Excel" showing a table of experimental data. The table has columns for Time, m, u, and v. The data is organized into multiple rows, with the first row starting at Time 0.00000 and the last row at Time 255.589. The table is titled "Felodipine" and "Ketoconazole".

Performed experiments



Controls and measured variables





# Set up (1)

## Parameter estimation

- Maximum likelihood algorithm
  - Maximises the probability that the model will predict the measurement values obtained from the experiments
  - Simultaneous estimation of:
    - parameters in the physical model of the process (e.g. growth and primary nucleation parameters)
    - **and** the variance model of the measuring instruments
- Kinetic model parameters


$$J_{prim} = k_n (\Delta C)^n$$

$$k_g \left( \frac{C_s - C_i}{C_i} \right)^g$$

## ■ Linear variance model

$$\sigma^2 = (\alpha z + \beta)^2 + \varepsilon$$

- $\sigma$  is the variance,  $z$  is the measurement
- $\alpha$  and  $\beta$  are relative and constant terms,  $\varepsilon$  is a small non-zero constant



# Set up (2)

## Parameter estimation

- Experiments used in estimation: Hold experimental data back for external validation
- Experimental data: Concentration measurements were thinned based on the local gradient (high gradients contain more information)
- Initial guesses: Iterative procedure repeating the parameter estimation multiple times changing initial guesses
- Upper and lower bounds: Ensure these are reasonable
- Estimating uncertain experimental conditions

Estimation (Sirius Felodipine PE)

Experiment	Include in estimation
exp_300ul	<input checked="" type="checkbox"/>
exp_350ul	<input type="checkbox"/>
exp_400ul	<input checked="" type="checkbox"/>
exp_450ul	<input checked="" type="checkbox"/>

Measurements Sort by: experiment then sensor Expand to level: 1

Group selected Ungroup selected Set variance model...

To estimate: 4 physical model parameters, and 0 variance model parameters

Experiments & measurements

Parameters to be estimated gPROMS language Properties

Estimation (Sirius Felodipine PE)

Parameter to be estimated	Unit	Initial gu...	Fixe...	Lower bo...	Upper bo...
Vessel001 → Bile molar concentration	mol/L	0.003000...	<input checked="" type="checkbox"/>	0.003000...	0.003000...
Vessel001 → Integration constant ("Freeform")	μm/s	0.01000...	<input type="checkbox"/>	1.00000E...	1.00000
Vessel001 → Integration order ("Freeform")	-	1.50000	<input type="checkbox"/>	0.500000	4.00000
Vessel001 → pH	-	6.50000	<input checked="" type="checkbox"/>	6.50000	6.50000
Vessel001 → Rate constant ("Freeform")	-	15.0000	<input type="checkbox"/>	10.0000	25.0000
Vessel001 → Order ("Freeform")	-	1.50000	<input type="checkbox"/>	0.500000	3.50000
Vessel001 → Alpha	-	1.50000	<input checked="" type="checkbox"/>	1.50000	1.50000
Vessel001 → Beta	-	2.00000	<input checked="" type="checkbox"/>	2.00000	2.00000
Add new					

To estimate: 4 physical model parameters, and 0 variance model parameters


Experiments & measurements Parameters to be estimated gPROMS language Properties

# Results



# Parameter estimation results

- **Single set of parameters** able to predict experimental measurements well
  - Were able to do this for a range of compounds
- 95% confidence intervals seem reasonable
  - Analyse with GSA




Compound	Ketoconazole	Aprepitant	Tadalafil	Felodipine	Indomethacin
Type	Dibase	Ordinary ampholyte	Neutral	Base	Acid
Growth integration constant	0.00886	0.00903	0.0865	0.00501	0.019
Growth integration order	0.904	2.10	1.52	3.44	1.69
Primary nucleation rate constant	17.5	13.8	16.5	14.6	13.9
Primary nucleation order	2.93	2.70	1.69	2.81	2.77

# Tadalafil *in vivo* performance

- 2.5 mg solution dose
- Using estimated parameters

Compound	Freeform	95% confidence interval
Growth integration constant	0.0865	0.035
Growth integration order	1.52	0.17
Primary nucleation rate constant	16.5	0.31
Primary nucleation order	1.69	0.16



# Future work





# Future work

- Include pharmacokinetics *in vivo* simulations
- Application of Sirius Analytical experimental systems
  - Impact of excipients
  - Transfer experiments
  - Biphasic dissolution
  - Solubility
- gPROMS FormulatedProducts gCOAS libraries
  - Utilise new association reaction equilibria capabilities to model the impact of excipients on performance

